Pluri (NASDAQ:PLUR) Posts Quarterly Earnings Results

Pluri (NASDAQ:PLUR) released its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, Zacks reports. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 1,701.19%.

Pluri Stock Performance

NASDAQ:PLUR traded up $0.31 during trading hours on Wednesday, reaching $4.45. 46,161 shares of the company’s stock were exchanged, compared to its average volume of 19,789. The company has a 50-day moving average of $4.34 and a 200 day moving average of $4.73. Pluri has a 1-year low of $3.22 and a 1-year high of $7.13. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 51.65. The firm has a market capitalization of $36.29 million, a price-to-earnings ratio of -0.86 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pluri in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pluri has an average rating of “Hold” and an average target price of $12.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors and hedge funds.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.